Eye最新文献

Background: Understanding the financial and environmental impact of clinical pathways is important for designing sustainable services. This study aimed to compare the cost and carbon footprint of sub-Tenon's and topical anaesthesia for cataract surgery, benchmark minimum topical anaesthesia utilisation rates, and quantify the benefits of increased topical anaesthesia usage in the United Kingdom National Health Service (NHS).

Methods: The cost and carbon footprint of products and staffing for topical and sub-Tenon's anaesthesia for cataract surgery were calculated and applied to National Ophthalmology Database audit data. A mainly process-based approach was used to estimate the carbon dioxide equivalent (CO2e) of product production, usage, and waste disposal.

Results: The typical CO2e per case was 0.71 kg for topical anaesthesia and 1.19 kg for sub-Tenon's anaesthesia. Around a third of CO2e was generated by usage of unneccesary equiptment and wasteful practices. The typical cost per case was £14.60-£17.14 for topical anaesthesia, £27.74 for sub-Tenon's anaesthesia performed by an operating department practitioner and £56.15 for sub-Tenon's anaesthesia performed by a consultant anaesthetist. It is estimated that around 25,000 NHS cataract cases could annually be converted from sub-Tenon's to topical anaesthesia, which would reduce the CO2e emissions of services by 12,000 kg while saving £265,000 on product usage and between £63,500 and £773,750 on staffing.

Conclusions: Topical anaesthesia is a cheaper and more environmentally sustainable alternative to sub-Tenon's anaesthesia for cataract surgery. Increased topical anaesthesia usage in cataract services could contribute towards the NHS aspiration of becoming "net zero" by 2040.

Clinical trials investigating drugs for various stages of age-related macular degeneration (AMD) are actively underway and there is a strong interest in outcomes that demonstrate a structure-function-correlation. The ellipsoid zone (EZ), a crucial anatomical feature affected in this disease, has emerged as a strong contender. There is significant interest in evaluating EZ metrics on Optical Coherence Tomography (OCT), such as integrity and reflectivity, as disruption of this photoreceptor-rich layer may indicate disease progression. Loss of photoreceptor integrity in the junctional zone of geographic atrophy (GA) has been shown to exceed the areas of retinal pigment epithelial (RPE) atrophy, thus predicting future GA expansion. Furthermore, reduced visual acuity and retinal sensitivity have been correlated with loss of EZ integrity, underscoring a structure-function relationship. Photoreceptor integrity has also recently been acknowledged by the Food and Drug Administration (FDA), supporting its use as a primary endpoint in clinical trials investigating treatments for GA. However, the segmentation of this EZ still poses challenges. Continuous enhancements in OCT resolution and advancements in automated segmentation algorithms contribute to improved assessment of the EZ, strengthening its potential as an imaging biomarker for assessing photoreceptor function. It remains to be seen whether the EZ will serve as a surrogate marker for intermediate AMD. This article aims to provide an overview of the current understanding and knowledge of the EZ, while addressing ongoing challenges encountered in its assessment and interpretation.

Objectives: To analyse peripapillary and papillary superficial microvascularization using OCT-angiography (OCT-A) in patients with non-arteritic ischaemic optic neuropathy (NAION) at the acute and resolutive stages.

Methods: This retrospective case-control study conducted between October 2018 and November 2019 included 23 NAION subjects at the acute stage (onset <1 month) and 20 patients at the resolutive stage (onset >3 months). NAION and contralateral eyes were compared to control eyes of patients (n = 50) matched 1:1 for refractive error, sex, age, systemic hypertension, diabetes, and sleep apnoea syndrome. The acquisition of OCT-A (OCTA-SD Cirrus 5000, Carl Zeiss) in 6 × 6 mm format centred on the papilla allowed measurement of the radial peripapillary plexus. A commercialized algorithm was used to obtain maps of density and microvascular retinal and papillary retinal perfusion, by positioning an ETDRS grid centred on the optic nerve head.

Results: There was significant decrease in peripapillary density and microvascular perfusion values for NAION eyes both at the acute and resolutive stages compared to the contralateral and control eyes, mainly in the temporal sectors. Papillary vascular density and perfusion were significantly increased in NAION and contralateral eyes compared to control eyes. There was no significant difference in peripapillary density or peripapillary vascular perfusion between contralateral and control eyes.

Conclusion: Eyes in the acute and resolutive phases of NAION exhibit decreased microvascular density and peripapillary capillary perfusion. Increased papillary vascular density and perfusion seem to be an intrinsic characteristic of the optic nerves of both eyes in patients who develop NAION.

Geographic atrophy (GA) is the advanced stage of non-neovascular (dry) age-related macular degeneration, defined by the presence of sharply demarcated atrophic lesions of the outer retina. The complement system is integral to the body's natural immune response, and hence its overactivation can lead to tissue damage and inflammation. It has been shown to play a significant role in GA lesion development and progression, and therefore, complement inhibition is emerging as a promising avenue for therapeutic intervention. With the recent approval by the Food and Drug Administration of drugs like SYFOVRE™ (pegcetacoplan injection) and IZERVAY™ (avacincaptad pegol intravitreal solution), there is hope for the development of interventions capable of slowing down or arresting the progression of GA. In particular, gene therapy intervention is gaining traction for halting GA atrophy at the source of our genes. The concept is to insert a gene into the eye that will act as an ocular "bio-factory," producing a desired protein. This can either lead to overproduction of an already available protein or produce a substance not typically generated in the eye. This review aims to provide an overview of the present understanding of GA, encompassing risk factors, prevalence, pathophysiology, and genetic associations. It will also highlight the current landscape of GA treatment, with particular emphasis on gene therapy intervention.

Objectives: To assess the visual outcome of extension to 12-weekly intervals (Q12W) following 4 loading doses of intravitreal Faricimab injections as described in the TENAYA and LUCERENE trials for the management of treatment-naïve neovascular Age-related Macular Degeneration (nAMD).

Methods: A retrospective analysis was carried out on all treatment-naïve nAMD patients who started Faricimab intravitreal injections in the period between 1^st September 2022 and 31^st January 2023. The data collection included best corrected visual acuity (BCVA) at baseline, 12 weeks, 24 weeks and 52 weeks; Central Subfield Thickness (CST) at baseline, 24 weeks and 52 weeks; Number of injections at 52 weeks; treatment intervals at 52 weeks. Descriptive and correlational analysis, independent and Paired-sample T-tests were used to analyse the data.